Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

NARecruitingINTERVENTIONAL

Enrollment

1,204

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Acute Ischemic Stroke

Interventions

DRUG

Human urinary kallidinogenase (HUK)

HUK (0.15 PNA) and sodium chloride injection (100ml), once per day

DRUG

Placebo

placebo (0 PNA) and sodium chloride injection (100ml), once per day

Trial Locations (1)

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Tiantan Hospital

OTHER